Bloomberg News (6/18, Feeley) reported, “Pfizer Inc. faces a Texas trial over its hormone-replacement drugs after a court overseeing lawsuits over the medicines sent 200 cases back to their home courts.”
At issue in the suit is whether “the Prempro [conjugated estrogens and medroxyprogesterone] menopause drug helped cause” the plaintiff’s breast cancer.
Over “8,000 lawsuits over the medicine consolidated in federal court in Arkansas” will be “returned for trial.” Still, “Pfizer…has won dismissals of more than 3,000 cases at either the pretrial stage or after the cases have been set for trials.”
Read full story here.